Consequenses for HRT following the HERS II and WHI reports: the primum non nocere is important, but translation into quo vadis is even more essential.
In the Nordic countries the prevalence of hormonal replacement therapy (HRT) use in women from 50 to 70 years of age is slightly above 30% evaluated by sales figures and with some variation between the five countries. The premise for this commentary is to discuss the best clinical practice when prescribing HRT to post menopausal women following the publication of the most recent evidence from two well conducted randomized placebo controlled trials, namely the Heart and Estrogen/Progestin Replacement Study II (HERS II) and the Women's Health Initiative study (WHI ).
Skouby
Sven
S
Department of Obstetrics and Gynecology, Frederiksberg Hospital, Copenhagen University Hospital, DK 2000 Copenhagen F, Denmark. sven.skouby@fh.hosp.dk
D000368:Aged; D001943:Breast Neoplasms / Q000209:etiology; D002318:Cardiovascular Diseases / Q000517:prevention & control; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004967:Estrogens / Q000009:adverse effects / Q000627:therapeutic use; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause; D011322:Primary Prevention; D011372:Progestins / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000592:standards; D012107:Research Design; D012307:Risk Factors
D004967:Estrogens; D011372:Progestins